Trial Profile

Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eculizumab (Primary)
Indications Guillain-Barre syndrome
Focus Therapeutic Use
Acronyms ICA-GBS
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

15 Mar 2017 Status changed from recruiting to discontinued.
06 Nov 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record
15 Nov 2014 Accrual to date is 3% according to United Kingdom Clinical Research Network record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com